Baldwin Wealth Partners LLC MA Sells 1,035 Shares of Edwards Lifesciences Corporation $EW

Baldwin Wealth Partners LLC MA lowered its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 15.6% during the 2nd quarter, Holdings Channel reports. The firm owned 5,613 shares of the medical research company’s stock after selling 1,035 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Edwards Lifesciences were worth $439,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Callan Family Office LLC boosted its position in Edwards Lifesciences by 316.6% in the second quarter. Callan Family Office LLC now owns 36,199 shares of the medical research company’s stock worth $2,831,000 after purchasing an additional 27,509 shares during the last quarter. Leo Wealth LLC boosted its position in Edwards Lifesciences by 1.4% in the second quarter. Leo Wealth LLC now owns 12,669 shares of the medical research company’s stock worth $991,000 after purchasing an additional 181 shares during the last quarter. Trifecta Capital Advisors LLC boosted its position in Edwards Lifesciences by 25,588.2% in the second quarter. Trifecta Capital Advisors LLC now owns 4,367 shares of the medical research company’s stock worth $342,000 after purchasing an additional 4,350 shares during the last quarter. Maryland State Retirement & Pension System boosted its position in Edwards Lifesciences by 2.1% in the second quarter. Maryland State Retirement & Pension System now owns 27,974 shares of the medical research company’s stock worth $2,188,000 after purchasing an additional 579 shares during the last quarter. Finally, Aurora Investment Managers LLC. purchased a new position in Edwards Lifesciences in the second quarter worth $212,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several research analyst reports. Mizuho boosted their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Wells Fargo & Company boosted their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research report on Thursday, August 7th. Morgan Stanley upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Royal Bank Of Canada upped their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.06.

Edwards Lifesciences Stock Performance

Shares of EW opened at $75.17 on Friday. The stock’s 50-day simple moving average is $78.20 and its 200 day simple moving average is $76.08. The stock has a market capitalization of $44.13 billion, a price-to-earnings ratio of 10.82, a price-to-earnings-growth ratio of 3.64 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $83.00.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.